Related Experiment Video
Updated: Mar 12, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma
ChunPing Yang1, ShuFeng Gao, HaiZhen Zhang
1Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background/Aims:
This study aims to investigate the effect of CD47 on the development of laryngeal squamous cell carcinoma (LSCC) and the therapeutic potential of monoclonal antibody against CD47 and its ligand SIRPα in the treatment of LSCC.
Methods:
We firstly detected the expressions of CD47 mRNA and protein in LSCC and para-carcinoma tissues, introduced the most efficient CD47siRNA sequence into LSCC cells by lentiviral transfection and employed three monoclonal antibodies to evaluate their anti-LSCC effects in vitro and in vivo.
Results:
We observed that the mRNA and protein expressions of CD47 in LSCC tissue had significant increase in LSCC tissues compared with those in para-carcinoma tissue (p < 0.05). After the treatments of three monoclonal antibodies, i.e. anti-SIRPα, anti-CD47 BRIC126, anti-CD47 B6H12.2, in rats transfected with Hep-2 cell, it has been showed that the mRNA and protein expressions of CD47 in LSCC tissue decreased, macrophage efficiency was promoted when anti-SIRPα and/or CD47siRNA were used, the amounts, viabilities and expressions of CD47 protein of tumor cell were significantly inhibited. Additionally, combined use of CD47siRNA and anti-SIRPα seemed more efficient than solo use of CD47siRNA/anti-SIRPα.
Conclusion:
The results suggested a critical role of CD47 in LSCC development and the promising treatment of antiCD47/SIRPα and/or CD47siRNA in LSCC.
Insights
CD47 plays a key role in laryngeal squamous cell carcinoma (LSCC) development. Targeting CD47 or SIRPα with monoclonal antibodies and CD47siRNA shows promising therapeutic potential for LSCC treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- CD47 is upregulated in laryngeal squamous cell carcinoma (LSCC) tissues.
- CD47 is implicated in the development and progression of LSCC.
Purpose of the Study:
- To investigate the role of CD47 in LSCC development.
- To evaluate the therapeutic efficacy of targeting CD47 and SIRPα in LSCC.
Main Methods:
- CD47 mRNA and protein expression were analyzed in LSCC and adjacent tissues.
- LSCC cells were transfected with CD47siRNA using lentiviral vectors.
- In vitro and in vivo anti-LSCC effects of monoclonal antibodies (anti-SIRPα, anti-CD47 BRIC126, anti-CD47 B6H12.2) were assessed.
Main Results:
- Significant increase in CD47 mRNA and protein expression observed in LSCC tissues.
- Monoclonal antibody treatments led to decreased CD47 expression in LSCC.
- Anti-SIRPα and/or CD47siRNA promoted macrophage efficiency and inhibited tumor cell viability and CD47 expression.
- Combined CD47siRNA and anti-SIRPα demonstrated superior efficacy compared to monotherapy.
Conclusions:
- CD47 plays a critical role in LSCC development.
- Targeting CD47 and SIRPα pathways, particularly with combined CD47siRNA and anti-SIRPα, offers a promising therapeutic strategy for LSCC.
More Related Videos
08:13Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
